CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies
about
Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment.Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature.Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies.New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.Interactions Between Therapeutic Proteins and Small Molecules: The Shared Role of Perpetrators and Victims.Physiologically based pharmacokinetic modeling as a tool to predict drug interactions for antibody-drug conjugates.Brentuximab vedotin: clinical updates and practical guidance.CYP Suppression in Human Hepatocytes by Monomethyl Auristatin E, the Payload in Brentuximab Vedotin (Adcetris®), is Associated with Microtubule Disruption.Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
P2860
Q36406979-714D4D5F-916A-4AE2-AA68-D15CC59E7648Q37384796-10A71AA5-678D-4F43-B406-D0B400196F89Q38218948-AB16D653-9EB8-405F-9525-FCCA11C7B117Q38643068-67AAE24D-AA75-4CD9-8103-F2A1F3E892A7Q38780827-C8877754-21BD-4156-918E-F445AE27643BQ38896683-DFA37305-4874-48EC-A4AD-2E24D9060497Q39047005-4C6813BF-3A82-4596-9F82-5F952767B72DQ45881591-D54D5663-362A-468E-A407-39C492ADDDFAQ49282959-FDD7ED16-0775-4325-83B2-E06CC5457691Q49629406-E0F88968-40D0-44D4-94C6-E0A6EF571196Q55412024-B4961700-0B18-490F-896F-DFADF5634048
P2860
CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CYP3A-mediated drug-drug inter ...... itive hematologic malignancies
@en
CYP3A-mediated drug-drug inter ...... tive hematologic malignancies.
@nl
type
label
CYP3A-mediated drug-drug inter ...... itive hematologic malignancies
@en
CYP3A-mediated drug-drug inter ...... tive hematologic malignancies.
@nl
prefLabel
CYP3A-mediated drug-drug inter ...... itive hematologic malignancies
@en
CYP3A-mediated drug-drug inter ...... tive hematologic malignancies.
@nl
P2093
P2860
P356
P1476
CYP3A-mediated drug-drug inter ...... itive hematologic malignancies
@en
P2093
Carmel M Lynch
Jeffrey V Matous
Laurie E Grove
Maureen Cooper
Owen A O'Connor
Radhakrishnan Ramchandren
Robert Chen
Stephen C Alley
P2860
P304
P356
10.1002/JCPH.116
P50
P577
2013-06-10T00:00:00Z